Armocad tablets

Generic Name: Anastrazole
Drug Class– Antineoplastic agent
Anastrozole is a third-generation aromatase inhibitor indicated for treatment of postmenopausal women with early and advanced breast cancer. It is also used in the adjuvant setting for the treatment of hormone receptor-positive breast cancer. It acts by reducing the availability of estrogen via inhibition of the aromatase enzyme.
Dosage and Administration

  • Recommended dose in breast cancer: 1 mg tablet taken once daily

Dosage Form and Strength

  • Supplied as tablets for oral use
  • Available in 1mg strength


Armocad (Anastrazole tablets) is an orally active anticancer drug.

Indications & Usage

Anastrazole is indicated for:

  • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer
  • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer
  • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.

Limitations of Use

  • Anastrazole rarely respond in patients with ER-negative disease and those who did not respond to previous tamoxifen therapy

Clinical Efficacy

  • Improves disease control, and decrease recurrence rates after cessation of treatment in postmenopausal women with hormone-responsive early breast cancer
  • Significantly reduces plasma estrogen levels with an improvement in response rates and quality of life in postmenopausal women with advanced breast cancer
  • Shows higher efficacy with significant improvement in the disease free survival, and occurrence of contra lateral breast cancer compared to tamoxifen
  • Reduces the risk of endometrial cancers, venous and arterial vascular effects as compared to tamoxifen

Safety Information

Adverse Reactions

  • The most common adverse events which occurs in women with early breast cancer (ATAC) includes hot flashes, nausea and vomiting, asthenia, arthritis, pain, arthralgia, pharyngitis, hypertension, depression, rash, osteoporosis, fractures, back pain, insomnia, headache, peripheral edema and lymphedema, regardless of causality
  • The most common adverse events which occurs in women with advanced breast cancer includes hot flashes, nausea, asthenia, pain, headache, back pain, bone pain, increased cough, dyspnea, pharyngitis and peripheral edema


  • It is contraindicated in patients with a known hypersensitivity to anastrazole and in women of premenopausal endocrine status, including pregnant women

Special Precautions

  • Consider risks and benefits before starting anastrazole treatment in women with pre-existing ischemic heart disease, as an increased incidence of ischemic cardiovascular events may occur with anastrazole use compared to tamoxifen use
  • Patients should be closely monitored for changes in bone mineral density and cholesterol, as anastrozole may affect bone mineral density and cholesterol levels
  • Do not use in combination with tamoxifen and estrogen containing products due to a risk of drug interactions
  • Caution should be used while dosing pediatric patients because efficacy of anastrazole has not been demonstrated for pubertal boys of adolescent age with gynecomastia or girls with McCune-Albright Syndrome and progressive precocious puberty